Phision Theraputics

Phision Theraputics

• 1.
  QUININIBS: MORE VISION,LESS NEEDLE. Life Sciences, Med Tec and Digital Health FutureHealth Summit Dublin May 2016 Breandán N. Kennedy Ph.D. Co-founder Phision Therapeutics Senior Lecturer (Pharmacology) UCD School of Biomolecular & Biomedical Science UCD Conway Institute DUBLIN, IRELAND. [email protected]
• 2.
  THE PROBLEM Blindness Ineffective& Inefficient Treatments US Retinal Therapeutics Market : $3.5 billion  Develop More Effective Drugs and Improved Drug Delivery Systems for Treatment of Blindness Linked to Diabetes or Ageing. OPPORTUNITY.
• 3.
  THE END USERS X PATIENT CLINICIANUSER  Pain 1: Clinical “Tsunami” of Eye Injections.  Pain 2: 30% Non-Responder Patients.  Pain 3: Risk of Eye Infection or Retinal Detachment.  Pain 1: Loss of Vision & Loss of Independence.  Pain 2: 6-12x Eye Injections Per Year.  Pain 3: No Alternative if Non-Responder or Refractory
• 4.
  FOUNDERS -Breandán Kennedy, Ph.D. -SeniorLecturer UCD -Vision Research (USA & Ireland) > 20 yrs -Jacintha O’Sullivan, Ph.D. -Associate Professor, TCD -Cancer research (USA & Ireland) > 20 yrs RESEARCH LEADERS -Alison Reynolds PhD -Ocular Drug Discovery. -Orla Galvin Ph.D. -Ocular Drug Delivery. -Clare Butler -Cancer Models. COLLABORATORS -Prof. A. Pandit. -Prof. A. Sjolander. -Prof. A. Stitt. -Prof. F. O’Brien FUNDERS ADVISORS -Consultant Ophthalmologists TEAMTHE TEAM
• 5.
  THE TECHNOLOGY DIFFERENTIATION Unbiased Drug Discovery In Vivo.  Novel Small Molecule Drugs.  Novel Mechanism of Action (non-VEGF).  Composition of Matter Patents.  Biodegradable Microcapsule Formulations  Sustained Release for 4-6 mo. ReductionistSystemic 10 micron drug-loaded microneedles
• 6.
  VEGFR* VEGF Decreased Leaky Blood Vessels X Anti-VEGF biologicsQUININIB CYSLTR1* cysLT Decreased Leaky Blood Vessels X Y NOVELTY & PROOF OF PRINCIPLE
• 7.
  SUSTAINED OCULAR DELIVERY
• 8.
  Mechanism of Action
• 9.
  Manufac. & Formulation INVESTMENT &RETURN Seed Funds €400K Series A €1000K Series B €4000K Pre-clinical Studies Phase I-II Studies * ** Yr 1 Yr 2 Yr 3 Yr 4 Yr 5 5 yr Cumulative Investment €400,000 €1,000,000 €0 €4,000,000 €0 €5,400,000 Costs €200,000 €120,000 €680,000 €300,000 €3,500,000 €4,800,000
• 10.
  Q-DRUGS. A NOVEL DRUGSERIES FOR BLINDNESS OF AGING & DIABETES. Dr. Breandán Kennedy B.Sc. Pharmacology, Ph.D. Pharmacology UCD Senior Lecturer in Pharmacology Lead Co-ordinator FP7 IAPP 3D-NET Director UCD Ocular Pharmacology Group Director UCD Zebrafish Facility UCD Conway Fellow Tel: +353 1-716-6740 [email protected]  Investment Capital  Domain Expertise  Business Networks  Track-Record  Synergy
• 12.
  Bridging Academia-Industry Barriers BreandánN. Kennedy Ph.D. Senior Lecturer & Head of Pharmacology UCD School of Biomolecular & Biomedical Science UCD Conway Institute [email protected]
• 13.
   Most AcademicResearch Groups Have The Ability To Commercialise Research.  Research Commercialisation Can Enhance Your Research Infrastructure, Capacity And Outputs.  Research Commercialisation can Support Economic Development and New Employment.  There Is A Need For Academic Groups & Funding Charities To Enhance Appreciation Of Research Commercialisation.  Research Commercialisation Is Challenging! “Executive” Summary
• 14.
   “Right Place,Right Time”- Meeting with Dr. Ruth McMahon (EI).  Awareness of lack of commercialisation knowledge.  Analysis of Commercialisation Potential (EI & Nova UCD).  IDF submitted to UCD TTO.  Awarded EI Proof-of-Concept award 2009-2010.  Completed UCD Innovation Workshop 2010.  Completed UCD Campus Company Development Programme 2011.  Introduction to Consultant Medicinal Chemist.  Awarded EI Commercialisation Fund 2012 (3rd time “lucky”).  Constructive feedback enhanced research proposal.  Priority/PCT patents filed and awarded 2011-2015.  Introduction to Industry Partners.  Awarded FP7 Industry-Academia Partnership Programme Award.  EI FP7 Co-ordinator support. Our Commercialisation Journey
• 15.
   Significantly enhancedour research expertise.  Expanded our research team.  Got us out of our “comfort zone”  Led to significant follow-on funding.  Generated patents and publications.  Resulted in research innovation awards.  Enhanced career development of research trainees.  Greater Interaction with Pharma, Clinicians, VCs, TTO.  Enhanced likelihood that our technology can be developed to clinic.  Jobs, Spin-Outs Benefits to Stakeholders
• 16.
   Terminology  Methodof Use, Composition of Matter, Prior Art, NCE…..  Mind-set  “how does it work” Vs “will someone buy/invest”  “papers” Vs “jobs”.  Patenting  Work intensive.  Non-disclosure.  Costs.  Market Research and Engagement with Stakeholders.  Commercial and Technical Deliverables/Milestones.  Gaining Trust, Building a Network. Challenges/Opportunities in Commercialisation.
• 17.
   Don’t assumeyour research has no commercial potential.  Seek help from commercialisation experts.  Contact TTOs, submit IDFs.  Review EI, SFI & IRC innovation/commercialisation awards.  Attend innovation workshops/Venture Launch programmes.  Build a network. Advice